Synlogic, Inc. (NASDAQ:SYBX) Short Interest Up 32.1% in May

Synlogic, Inc. (NASDAQ:SYBX) was the recipient of a large increase in short interest in the month of May. As of May 31st, there was short interest totalling 37,900 shares, an increase of 32.1% from the May 15th total of 28,700 shares. Approximately 0.5% of the shares of the company are sold short. Based on an average trading volume of 10,600 shares, the days-to-cover ratio is currently 3.6 days.

Synlogic Trading Down 1.2%

Shares of SYBX opened at $1.23 on Thursday. The stock has a market capitalization of $14.33 million, a PE ratio of -0.49 and a beta of 0.51. The firm’s 50 day moving average is $1.14 and its 200-day moving average is $1.28. Synlogic has a 12 month low of $0.90 and a 12 month high of $1.88.

About Synlogic

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.